For instance, CD47-blocking antibodies in combination with tumor-opsonizing antibodies significantly increased the antitumor activity of neutrophils in vitro and in vivo [39,40,41,42], whereas knockdown of CD47 increased the killing of breast cancer cells by neutrophils [43]. This evidence concerns the gene CD47 and breast carcinoma.